Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

3.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.0K
Complement System01:27

Complement System

11.7K
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...
11.7K
Humoral Immune Responses01:36

Humoral Immune Responses

85.2K
Overview
85.2K
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

17.6K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
17.6K
Hypersensitivity Reactions: Cytolytic Reactions01:01

Hypersensitivity Reactions: Cytolytic Reactions

81
Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
81
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

85.5K
Overview
85.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update.

Annals of the rheumatic diseases·2026
Same author

Genetic Variants of the Human Thiamine Transporter (<i>SLC19A3</i>, THTR2)-Potential Relevance in Metabolic Diseases.

International journal of molecular sciences·2025
Same author

[Interdisciplinary consensus statement about the diagnosis and treatment of chronic fatigue syndrome/myalgic encephalomyelopathy].

Orvosi hetilap·2025
Same author

T cell immunity ameliorates COVID-19 disease severity and provides post-exposure prophylaxis after peptide-vaccination, in Syrian hamsters.

Frontiers in immunology·2023
Same author

Targeted suppression of Dpt-specific B cells in humanized Rag2- γc- mouse model of HDM allergy.

Scandinavian journal of immunology·2022
Same author

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.

Annals of the rheumatic diseases·2022

Related Experiment Video

Updated: Mar 10, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

18.8K

Complement Receptor Type 1 Suppresses Human B Cell Functions in SLE Patients.

Mariann Kremlitzka1, Bernadett Mácsik-Valent2, Anna Polgár3

  • 1MTA-ELTE Immunology Research Group, Budapest, Eötvös Loránd University, Pázmány Péter s. 1/C, Budapest 1117, Hungary.

Journal of Immunology Research
|December 17, 2016
PubMed
Summary

Complement receptor type 1 (CR1) inhibits B cell activation by reducing early signaling. Even with lower expression in lupus patients, CR1 retains its inhibitory function, suggesting therapeutic potential.

More Related Videos

Measuring Erythrocyte Complement Receptor 1 Using Flow Cytometry
07:20

Measuring Erythrocyte Complement Receptor 1 Using Flow Cytometry

Published on: May 19, 2020

7.8K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K

Related Experiment Videos

Last Updated: Mar 10, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

18.8K
Measuring Erythrocyte Complement Receptor 1 Using Flow Cytometry
07:20

Measuring Erythrocyte Complement Receptor 1 Using Flow Cytometry

Published on: May 19, 2020

7.8K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K

Area of Science:

  • Immunology
  • Cell Biology
  • Autoimmunity

Background:

  • Complement receptors (CRs) are crucial for innate and adaptive immunity.
  • Complement receptor type 1 (CR1, also known as CD35) was previously identified as an inhibitor of B cell receptor (BCR)-induced functions.

Purpose of the Study:

  • To investigate the mechanism by which CR1 inhibits B cell activation.
  • To assess the functional capacity of CR1 on B cells from patients with systemic lupus erythematosus (SLE).

Main Methods:

  • Studied the effect of CR1 ligation on BCR-induced phosphorylation of Syk and MAPKs in human B lymphocytes.
  • Compared CR1 expression levels and inhibitory function on B cells from healthy individuals and SLE patients.

Main Results:

  • CR1 ligation inhibits early B cell activation by reducing phosphorylation of key signaling molecules like Syk and MAPKs.
  • B lymphocytes from active SLE patients exhibit lower CR1 expression but retain CR1's inhibitory capacity.
  • Ligand-induced clustering of CR1 significantly inhibits major B cell functions in SLE patients, similar to healthy individuals.

Conclusions:

  • Reduced CR1 expression in SLE patients does not impair its inhibitory function on B cell activation.
  • CR1 (CD35) represents a promising therapeutic target for reducing B cell activation and autoantibody production in autoimmune diseases like SLE.